Paras Biopharmaceuticals Finland Oy

Paras Biopharmaceuticals
A Significant Growth Story



A Significant Growth Story

Paras Biopharmaceuticals Finland Oy
Kiviharjunlenkki 10, Oulu, Finland

August 2026

Company Overview



A Significant Growth Story

"Paras Biopharmaceuticals is a Finland based biopharmaceuticals company – Company focus is to create unique solutions for unmet medical needs"

Business model of Paras Biopharmaceuticals is based on "Deep Dive Analysis" of available medicines / medical solutions for human diseases.

Paras Biopharmaceuticals



Paras Biopharmaceuticals



The Starting Point

Paras Biopharmaceuticals was started in 2013 by a group of biopharma professionals, process engineers with strong industry background and experience of creating biologics and their production technologies.

One of the first tasks performed by the company and its professionals (with more that 20+ years of industry experience) was a situational analysis to identify critical gaps and future opportunities.

Situation Analysis of Medicine/Diseases

A thorough analysis reveled two major issues

Issue 1: There are unmet medical need for rare and orphan diseases – New and effective medicines are needed.

Issue 2: Existing recombinant biologics offer solutions, but they are very high priced and out of reach of many patients.

Technology Gap Analysis -Business Opportunity

Paras Biopharma analysis reveled 2 major gaps:

Gap Analysis - Gap 1 – Recombinant biologics (as medicine) offer solutions, but recombinant medicines are very high priced.

- **Root cause?** – manufacturing processes for many medicines are inefficient as they are based on 20 years old manufacturing processes.
  - **Critical Needs?** – New scientific biomanufacturing technologies are needed and this open significant business opportunities.

Technology Gap Analysis - Business Opportunity

Gap Analysis - Gap 2 – There are no efficient medicines for some rare and orphan diseases – unmet medical needs.

- **Critical Needs** – Solutions for unmet medical needs opens up new business opportunities. Repurposing of complex biologics will see significant demand.

Based on “Deep Dive Analysis” Paras Team identified and from 2013 achieved the following:

1) Developed a technology platform which enables complex biologics.

2) Company develops/carries out scale-up & produces biologics.

3) Provides biologics development & CDMO services.

Paras Biopharma's Journey: 2014 to 2022 Major Developments

Paras Biopharma has worked & achieved major successes in the following:

- Developed a unique biologics development technology platform. It comprises of 4 technologies – Diabrid™, NobleCleav™, Biomultifold™ and StructQuant™.
- Company has made a full acquisition & have full ownership of a state-of-art biologics production plant in Finland.
- The team has applied its technologies to high value biologics (possessing significant manufacturing challenges) & have successfully produced active biologics.

Paras Biopharma's Journey: 2019 to 2026
Major Developments

Paras Biopharma has successfully achieved the following:

- Paras Biopharma team developed scale-up production technology for IL1-RA (Anakinra) – A product with significant applications in un-met medical needs, rare diseases and new treatment (Covid).
- Company has developed production technology for Recombinant bioprocess enzymes – Enterokinase (EK) and TEV Protease (TEV), both in E. coli.

Paras Biopharma's Journey: 2021 to 2026
Major Developments

Paras Biopharma has successfully achieved the following: (cont)

- Company has developed biosimilar production technologies for Recombinant Teriparatide (Foreto® Biosimilar), Recombinant IL1-RA (Kineret® biosimilar) & Recombinant Romiplostim (N-plate® biosimilar).
- Developed & achieved initial development of Insulin Aspart & Rasburicase (Elitek®).

Forteo®, Kineret®, N-plate® and Elitek® are trademarks of Eli Lilly, Swedish Orphan Biovitrum, Amgen and Sanofi Aventis respectively

Fast Forward 2026

Paras Biopharma team is working in the following areas



Discovery & Development Services: Paras Biopharma is creating solutions (solving problem biologics) for biopharma companies.



Biologics Development & Scale-up: Paras Biopharma team is taking on scale-up production projects for medium & big pharma clients.



Biologics Materials (Bulk): Paras Biopharma is producing biologics Bulk for other companies in USA/Europe for pre-IND, IND submissions (CDMO+ model).



High value Biosimilars: Paras Biopharma is getting closer to licensing out biologics (biosimilars) for Immuno-oncology, Knee Osteoarthritis, Diabetes, Rheumatoid Arthritis, & Osteoporosis (total 4 products).

Paras Biopharma:
Key Developments, Journey & Achievements



2013

Paras Biopharma is established in **Oulu, Finland**

2016

Develops **Diabrid™**, **NobleCleav™** & **Biomultifold™** technologies for biologics

2017

Full ownership of **biologics production plant** in Finland

2018

Develops technology for **EK / TEV**

Develops **production technology** for **IL1-RA (Anakinra)** – Scale-up production starts

2020

Multiple clients for **CDMO** & development services

2023

Successfully develops **Romiplostim peptibody for ITP (N-plate®)**

Starts biologic **CDMO** activities

2025

Receives tailored **Scientific Advice** from the **European Medicines Agency (EMA)**


Pivotal PK study on healthy volunteers & **Phase III waiver** for Paras Romiplostim

2026

Licensing discussions ongoing for **Biosimilar pipeline**


Fast Forward 2026

Today, Paras Biopharma is offering services in 3 major areas – All 3 offerings are growing rapidly & presents significant growing opportunities.




Biologics CDMO is Growing


Expanding demand in all production areas



Promising Market Prospectus for Biologics CDMO



Rapid biosimilar uptake in both USA & Europe



Repurposing Unmet Medical Needs

Market potential of IL1-RA as a bio-better/novel application


Global respiratory diseases drug market is pegged at $90.3 billion in 2020 and is expected to grow at a CAGR of 7% and reach US$ 126.6 billion by 2025.	Global osteoarthritis therapeutics markets is projected to reach $11.0 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 8.7% from 2020 to 2025.	Gout Therapeutics Market will be worth $8.3 Billion By 2025 at a CAGR of 16.1%.	Global multiple myeloma market size stood at $19.48 billion in 2018 and is projected to reach $31.00 billion by 2026, exhibiting a CAGR of 6.0% during the forecast period.
Respiratory Rare Diseases	Knee Osteoarthritis	Gout	Multiple Myeloma

Repurposing Unmet Medical Needs

The Opportunity


Paras Biopharmaceuticals offers an opportunity to explore development of bio-better IL-1 RA formats opening up $130 bn worth of market opportunity.

Paras Biopharmaceuticals now looks forward to partnering with biopharmaceutical companies with an interest to develop IL-1 RA as a bio-better or as a novel formulation for novel applications.



Section 2

Uniqueness of Paras Biopharma Technologies & Solutions




Paras Biopharmaceuticals Finland Oy


August 2026 Paras Biopharma Technologies & Solutions

Proprietary Diabrid™ platform enables high-yields & low unit cost

Paras – patented platform allows regulation of production intensity…



…leading to higher yield and lower cost



Proprietary Diabrid™ platform enables high-yields & low unit cost



Section 3

Summary of Paras Biopharma Technologies: Advantages & Offerings

Paras Biopharmaceuticals Finland Oy

August 2026 Review of Paras Technologies & Offerings



Paras Biopharmaceuticals Finland Oy

Paras Biopharma Biologics addresses €15 Billion market opportunity growing at 15% CAGR.





Paras Biopharmaceuticals Finland Oy

Paras Biopharma platform technologies are built on 20+ years of strong technology knowledge & hard work.

Paras Biopharmaceuticals Finland Oy

Paras Biopharma technologies enables difficult to manufacture biologics.



Paras Biopharmaceuticals Finland Oy

"Paras proprietary Diabrid™ technology platform (StructQuant™ technology) enables high-yield and low unit cost"





“Paras Proprietary Diabrid™ Platform including StructQuant™ Technology enables high-yield and low unit cost”



Fully owned state-of-art biologics production plant in Finland–offers biologics CDMO+ services, advantage of significant low cost of biosimilar / new biologics development.

Paras Biopharma is developing & supplying to its USA customer biologics for unmet medical needs.



Section 4

Paras Biopharma: Product Pipeline, Status & Time to Market

Paras Biopharmaceuticals Finland Oy

August 2026 Target Product Pipeline



Focusing on High Value Therapeutic Areas

- Company's portfolio services are focused on high value therapeutic medicine and unmet medical needs.

Therapeutic Area	Molecule	Stage
Respiratory	IL1-RA	IND submission
Osteo arthritis	IL1-RA	Paras material successfully test in UK labs / discussions with companies
Oncology	IL1-RA	Multiple myeloma
Biosimilar Technologies:	Romiplostim	Advance stage scale-up production optimization ongoing.
Oncology – ITP	Rasburicase	Successful product development achieved
Osteoporosis	Teriparatide	40+ batches carried out / external characterization
R.A	IL1-RA	20+ batches carried out – material tested
Diabetes	Analog Insulin	Strong exp – smalls scale tech development

Paras Biopharma Bioprocess Enzymes






Section 5

Paras Biopharma: Our Foundation in Science- Bringing Innovative Solutions

Paras Biopharmaceuticals Finland Oy

August 2026 Process Development & Management Team



Paras Biopharmaceuticals: The Team

Our core foundation is “science & innovative solutions”.


The foundation of Paras Biopharma work is to do interesting scientific work and bring innovative solutions.

“Our core strength is our team and our interest in science to study biomanufacturing challenges”

PARAS BIOPHARMACEUTICALS FINLAND OY



Dr Ashesh Kumar
CEO & Director –
Biologics & Licensing



Dr Hans Söderlund
Director –
Global Strategic Alliance



Dr Mark Jackson
Administration Lead



Mr Martti Särkelä
Business Advisor

Leadership team with diverse experience

Paras Biopharma: Driven by a team with 20+ years of strong technical knowledge



Paras Biopharmaceuticals

Advisory board

Section 6

Business Plan & Revenue Streams

Paras Biopharmaceuticals Finland Oy

August 2026 Business Plan, Business Model & Financials



Section 7


Past Performance


Paras Biopharmaceuticals Finland Oy

August 2026 Business Plan, Business Model & Financials



Paras Biopharma Past Performance (2019 – 2022)





Financial Highlights & Summary

- A Growing Debt-Free company.
- Revenue generating.
- Multiple clients in USA & Europe.
- Revenue from discovery services, biologics bulk supplies, biologics CDMO services, bioprocess enzymes sales.
- Revenue 50:50 from USA & Europe.
- Profit making – Revenue from biosimilar licensing expected in 2026.

Section 9

Paras Biopharma: Preview of Biologics Production Plant in Finland.



Paras Biopharmaceuticals Finland Oy

August 2026

Production Infrastructure, Labs and Production Setup.

Paras Biopharma Production Suite



Paras Biopharma Facility Support Systems



Paras Production Facility – Offering Contract Manufacturing and Collaboration on Product Development








ADDRESS
Paras Biopharmaceuticals Finland Oy
Kiviharjunlenkki 10, 90220 OULU, Finland
Phone: +358 442 709 462

EMAIL

info@parasbiopharma.com

SOCIAL

www.parasbiopharma.com
www.linkedin.com/company/paras-biopharma-finland



Confidentiality & Disclaimer

By accepting these materials, the recipient agrees to be bound by the following obligations and limitations.

This presentation, including information contained in this disclaimer, is given to you in strict confidence. By receiving the presentation, you agree that no part of this presentation or disclaimer October be disclosed, distributed or reproduced to any third party without the consent of Paras Biopharmaceuticals Finland Oy ("PARAS").

This presentation is being provided for the sole purpose of providing the recipients with background information about PARAS business and bio-business in general. This presentation, including the information contained in this disclaimer, does not constitute an offer, invitation or recommendation to subscribe for or purchase any security and neither the presentation, disclaimer nor anything contained in them forms the basis of any contract or commitment.

Purpose. These materials have been prepared by for the exclusive use of the party to whom PARAS delivers these materials (together with its subsidiaries and affiliates, hereinafter the "Recipient").

No independent verification. The information in these materials have been obtained from the Recipient and/or other publicly available sources and has not been independently verified by PARAS and/or its subsidiaries, branches or affiliates (together, the " PARAS ") or any of their respective directors, officers, employees, agents, representatives or advisors (the "Representatives") or any other person.

No representation or warranty. No representation, warranty, or undertaking, either express or implied, is or will be given by PARAS or its Representatives as to or in relation to the accuracy, completeness, reliability or sufficiency of the information contained in these materials or as to the reasonableness of any assumption contained in these materials.

No liability. By accepting receipt of these materials, the Recipient acknowledges and agrees that to the maximum extent permitted by law and except in the case of fraud, each of PARAS and its Representatives expressly disclaims any and all liability that October arise from these materials.

No duty to update. These materials speak as at the date hereof (unless an earlier date is otherwise indicated in these materials) and in furnishing these materials, no obligation is undertaken nor is any representation or undertaking given by PARAS or its Representatives to provide the Recipient with additional information or to update, revise or reaffirm the information in these materials or to correct any inaccuracies therein which October become apparent.

Information only. These materials have been prepared solely for informational or educational purposes and do not suggest taking or refraining from any action. They do not constitute or contain an invitation, solicitation or an offer to buy or sell any securities or related financial instruments or any of the assets, business, or undertakings described herein, and they do not constitute, and should not be construed as, a proposal, a commitment or an offer to arrange, underwrite, syndicate or otherwise provide any debt financing.

No distribution. These materials have been prepared on a confidential basis solely for your use and benefit; provided that you and any of your employees, representatives, or other agents October disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the transaction and all materials of any kind (including opinions or other tax analyses) that are provided to you relating to such tax treatment and tax structure. Distribution of these materials to any person other than you and those persons retained to advise you, who agree to maintain the confidentiality of these materials and be bound by the limitations outlined herein, is unauthorized.

PARAS specifically prohibits the redistribution or reproduction of these materials in whole or in part without the prior written permission of PARAS and PARAS accepts no liability whatsoever for the actions of third parties in this respect.